1. Home
  2. FIGR vs BLTE Comparison

FIGR vs BLTE Comparison

Compare FIGR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FIGR

Figure Technology Solutions Inc.

HOLD

Current Price

$40.50

Market Cap

7.0B

Sector

Finance

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$143.50

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIGR
BLTE
Founded
2018
2018
Country
United States
United States
Employees
602
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FIGR
BLTE
Price
$40.50
$143.50
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$53.22
$198.00
AVG Volume (30 Days)
3.7M
83.6K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.23
N/A
Revenue Next Year
$24.25
$492.11
P/E Ratio
$134.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.01
$56.68
52 Week High
$78.00
$200.00

Technical Indicators

Market Signals
Indicator
FIGR
BLTE
Relative Strength Index (RSI) 59.75 31.93
Support Level $40.30 $103.94
Resistance Level $42.98 $172.02
Average True Range (ATR) 3.01 5.92
MACD 0.58 -1.24
Stochastic Oscillator 67.34 6.08

Price Performance

Historical Comparison
FIGR
BLTE

About FIGR Figure Technology Solutions Inc.

Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: